Combination treatment of polo-like kinase 1 and tankyrase-1 inhibitors enhances anticancer effect in triple-negative breast cancer cells

Geun Hyoung Ha; Dong Young Kim; Eun Kyoung Breuer; Chung Kwon Kim

doi:10.21873/anticanres.12352

Combination treatment of polo-like kinase 1 and tankyrase-1 inhibitors enhances anticancer effect in triple-negative breast cancer cells

Geun Hyoung Ha, Dong Young Kim, Eun Kyoung Breuer, Chung Kwon Kim

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Background/Aim: Breast cancer is the most common malignant cancer type in women, and triple-negative breast cancer (TNBC) is an extremely aggressive subtype of breast cancer with poor prognosis rates. The present study investigated the antitumor effect of polo-like kinase 1 (PLK1) inhibitor in combination with the tankyrase-1 (TNKS1) inhibitor on TNBC cells. Materials and Methods: We evaluated the antitumor effects of combination therapy with PLK1 and TNKS1 inhibitor using cell viability analysis, apoptosis assay and transwell assay for cell invasion and migration in TNBC cells. Results: Combination treatment with PLK1 and TNKS1 inhibitors not only inhibited the invasion and migration capacity of TNBC cells, but also increased the apoptosis and cell death of TNBC cells. The viability of TNBC cells with low expression of β-catenin and high expression of PLK1 was not affected by treatment with PLK1 inhibitor. However, the combination treatment with the TNKS1 inhibitor significantly decreased cell invasion and migration and increased apoptosis. Conclusion: Combination therapy of PLK1 and TNKS1 inhibitors may improve the therapeutic efficacy of the current treatment for TNBC.

Original language	English (US)
Pages (from-to)	1303-1310
Number of pages	8
Journal	Anticancer research
Volume	38
Issue number	3
DOIs	https://doi.org/10.21873/anticanres.12352
State	Published - Mar 2018
Externally published	Yes

Keywords

Apoptosis
Breast cancer cells
Combination therapy
Polo-like kinase 1
Tankyrase-1

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.21873/anticanres.12352

Cite this

@article{a8265bed2d4843e7bf070c8d3c5be038,

title = "Combination treatment of polo-like kinase 1 and tankyrase-1 inhibitors enhances anticancer effect in triple-negative breast cancer cells",

abstract = "Background/Aim: Breast cancer is the most common malignant cancer type in women, and triple-negative breast cancer (TNBC) is an extremely aggressive subtype of breast cancer with poor prognosis rates. The present study investigated the antitumor effect of polo-like kinase 1 (PLK1) inhibitor in combination with the tankyrase-1 (TNKS1) inhibitor on TNBC cells. Materials and Methods: We evaluated the antitumor effects of combination therapy with PLK1 and TNKS1 inhibitor using cell viability analysis, apoptosis assay and transwell assay for cell invasion and migration in TNBC cells. Results: Combination treatment with PLK1 and TNKS1 inhibitors not only inhibited the invasion and migration capacity of TNBC cells, but also increased the apoptosis and cell death of TNBC cells. The viability of TNBC cells with low expression of β-catenin and high expression of PLK1 was not affected by treatment with PLK1 inhibitor. However, the combination treatment with the TNKS1 inhibitor significantly decreased cell invasion and migration and increased apoptosis. Conclusion: Combination therapy of PLK1 and TNKS1 inhibitors may improve the therapeutic efficacy of the current treatment for TNBC.",

keywords = "Apoptosis, Breast cancer cells, Combination therapy, Polo-like kinase 1, Tankyrase-1",

author = "Ha, {Geun Hyoung} and Kim, {Dong Young} and Breuer, {Eun Kyoung} and Kim, {Chung Kwon}",

note = "Funding Information: This work was supported by the National Research Foundation of Korea(NRF) Grant funded by the Korean Government(MSIP) (NRF-2015R1D1A1A01058623, 2016R1A5A2945889 and 2016R1 6A3A11930537). Publisher Copyright: {\textcopyright} 2018 International Institute of Anticancer Research. All rights reserved.",

year = "2018",

month = mar,

doi = "10.21873/anticanres.12352",

language = "English (US)",

volume = "38",

pages = "1303--1310",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "3",

}

TY - JOUR

T1 - Combination treatment of polo-like kinase 1 and tankyrase-1 inhibitors enhances anticancer effect in triple-negative breast cancer cells

AU - Ha, Geun Hyoung

AU - Kim, Dong Young

AU - Breuer, Eun Kyoung

AU - Kim, Chung Kwon

N1 - Funding Information: This work was supported by the National Research Foundation of Korea(NRF) Grant funded by the Korean Government(MSIP) (NRF-2015R1D1A1A01058623, 2016R1A5A2945889 and 2016R1 6A3A11930537). Publisher Copyright: © 2018 International Institute of Anticancer Research. All rights reserved.

PY - 2018/3

Y1 - 2018/3

N2 - Background/Aim: Breast cancer is the most common malignant cancer type in women, and triple-negative breast cancer (TNBC) is an extremely aggressive subtype of breast cancer with poor prognosis rates. The present study investigated the antitumor effect of polo-like kinase 1 (PLK1) inhibitor in combination with the tankyrase-1 (TNKS1) inhibitor on TNBC cells. Materials and Methods: We evaluated the antitumor effects of combination therapy with PLK1 and TNKS1 inhibitor using cell viability analysis, apoptosis assay and transwell assay for cell invasion and migration in TNBC cells. Results: Combination treatment with PLK1 and TNKS1 inhibitors not only inhibited the invasion and migration capacity of TNBC cells, but also increased the apoptosis and cell death of TNBC cells. The viability of TNBC cells with low expression of β-catenin and high expression of PLK1 was not affected by treatment with PLK1 inhibitor. However, the combination treatment with the TNKS1 inhibitor significantly decreased cell invasion and migration and increased apoptosis. Conclusion: Combination therapy of PLK1 and TNKS1 inhibitors may improve the therapeutic efficacy of the current treatment for TNBC.

AB - Background/Aim: Breast cancer is the most common malignant cancer type in women, and triple-negative breast cancer (TNBC) is an extremely aggressive subtype of breast cancer with poor prognosis rates. The present study investigated the antitumor effect of polo-like kinase 1 (PLK1) inhibitor in combination with the tankyrase-1 (TNKS1) inhibitor on TNBC cells. Materials and Methods: We evaluated the antitumor effects of combination therapy with PLK1 and TNKS1 inhibitor using cell viability analysis, apoptosis assay and transwell assay for cell invasion and migration in TNBC cells. Results: Combination treatment with PLK1 and TNKS1 inhibitors not only inhibited the invasion and migration capacity of TNBC cells, but also increased the apoptosis and cell death of TNBC cells. The viability of TNBC cells with low expression of β-catenin and high expression of PLK1 was not affected by treatment with PLK1 inhibitor. However, the combination treatment with the TNKS1 inhibitor significantly decreased cell invasion and migration and increased apoptosis. Conclusion: Combination therapy of PLK1 and TNKS1 inhibitors may improve the therapeutic efficacy of the current treatment for TNBC.

KW - Apoptosis

KW - Breast cancer cells

KW - Combination therapy

KW - Polo-like kinase 1

KW - Tankyrase-1

UR - http://www.scopus.com/inward/record.url?scp=85043445741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043445741&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12352

DO - 10.21873/anticanres.12352

M3 - Article

C2 - 29491053

AN - SCOPUS:85043445741

SN - 0250-7005

VL - 38

SP - 1303

EP - 1310

JO - Anticancer research

JF - Anticancer research

IS - 3

ER -

Combination treatment of polo-like kinase 1 and tankyrase-1 inhibitors enhances anticancer effect in triple-negative breast cancer cells

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this